IN8bio Strengthens Intellectual Property Portfolio with Newly Granted Global Patents

<p>Newly granted patents expand the use of the DeltEx Drug Resistant Immunotherapy (DRI) platform to encompass Chimeric Antigen Receptor T-cell (CAR-T) and checkpoint inhibitors (CPIs). Broadens IN8bio’s foundational intellectual property (IP) for its proprietary DeltEx DRI platform which covers the use of any genetic modification that conveys chemotherapy resistance in gamma-delta T cells, as well [&#8230;]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/in8bio-strengthens-intellectual-property-portfolio-with-newly-granted-global-patents/">IN8bio Strengthens Intellectual Property Portfolio with Newly Granted Global Patents</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>